Journal article
Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies
M Martinello, M Hellard, D Shaw, K Petoumenos, T Applegate, J Grebely, B Yeung, L Maire, D Iser, A Lloyd, A Thompson, J Sasadeusz, P Haber, GJ Dore, GV Matthews
Antiviral Therapy | INT MEDICAL PRESS LTD | Published : 2016
DOI: 10.3851/IMP3035
Abstract
Background: Individuals with recent HCV infection may beneit from shortened duration therapy. These studies evaluated the eficacy and safety of response-guided regimens with pegylated interferon-α2a and ribavirin for people with recent HCV infection. Methods: Participants with recent hepatitis C (duration of infection ≤18 months) enrolled in the ATAHC II (pegylated interferon-α2a ± ribavirin) and DARE-C I (pegylated interferon- α2a, ribavirin and telaprevir) studies were included for analysis. Treatment duration was response-guided (ATAHC II: 8, 16, 24 or 48 weeks; DARE-C I: 8, 12 or 24 weeks) and dependent on time to irst undetectable HCV RNA using Roche Taqman HCV RNA testing. The primary ..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. The Burnet Institute receives funding from the Victorian Operational Infrastructure Support Program. Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under award R01DA015999 and Janssen-Cilag Pty Ltd. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. JG and GVM are supported through NHMRC Career Development Fellowships. GJD and AL are supported through NHMRC Practitioner Fellowships.